Research Use Only - Not for human consumption. 18+ only.
Clinical TrialsMetabolic & Weight LossSubcutaneous

Retatrutide

Also known as: LY3437943

Retatrutide is a triple agonist (GIP, GLP-1, and glucagon receptor) showing exceptional weight loss results in clinical trials. It represents the next generation beyond tirzepatide.

Research Status

Clinical Trials

Phase 3 clinical trials

For research purposes only. Not approved for human use. Not medical advice.

Research Areas

Exceptional weight loss (up to 24% body weight)
Improves insulin sensitivity
Reduces appetite significantly
Improves metabolic health
May preserve lean mass
Cardiovascular benefits

Side Effects

Nausea
CommonMild

Most common during dose escalation, typically resolves within 1-2 weeks as the body adapts. Occurs in 40-50% of users. Manage by eating smaller, frequent meals; avoiding fatty or greasy foods; and staying hydrated. Take anti-nausea medication (e.g., ginger, vitamin B6) if needed. Usually improves significantly by week 3-4 of each dose level.

Vomiting
UncommonModerate

Occurs in approximately 5-15% of users, usually during the first 2-4 weeks of treatment or after dose increases. If vomiting persists beyond 48 hours or is severe, contact a healthcare provider. Ensure adequate hydration to prevent dehydration. May indicate need to slow titration schedule.

Diarrhea or loose stools
CommonMild

Reported in 20-30% of users, typically mild and self-limiting. Related to slowed gastric emptying and increased GLP-1 signaling. Manage with increased fiber intake, hydration, and over-the-counter antidiarrheal agents if needed. Usually resolves within 1-2 weeks.

Constipation
UncommonMild

Can occur in 10-15% of users, particularly during dose escalation. Manage with increased water intake (aim for 2-3 liters daily), dietary fiber, and light physical activity. Over-the-counter stool softeners or osmotic laxatives (e.g., polyethylene glycol) are safe options. Contact healthcare provider if constipation persists beyond 1 week.

Decreased appetite
CommonMild

This is an intended pharmacological effect and the primary mechanism for weight loss. Appetite suppression is dose-dependent and typically increases with each titration step. Ensure adequate protein and micronutrient intake despite reduced appetite to prevent malnutrition.

Injection site reactions (redness, swelling, bruising)
UncommonMild

Occurs in 5-10% of users. Minimize by rotating injection sites systematically, using proper injection technique, and allowing the solution to reach room temperature before injection. Most reactions resolve within 24-48 hours. Apply ice if swelling occurs. Avoid injecting into the same site repeatedly.

Headache
UncommonMild

Reported in approximately 5-10% of users, often during the first 1-2 weeks of treatment. Usually self-resolving. Ensure adequate hydration and sleep. Over-the-counter analgesics (acetaminophen or ibuprofen) are safe if needed.

Fatigue or low energy
UncommonMild

Occurs in 5-8% of users, particularly during rapid weight loss or if caloric intake is too restricted. Ensure adequate protein intake (minimum 1.2g per kg body weight), sufficient sleep, and gradual caloric deficit rather than extreme restriction. Usually improves with time and proper nutrition.

Dizziness or lightheadedness
UncommonMild

May occur due to rapid weight loss, dehydration, or electrolyte imbalance. Ensure adequate fluid and electrolyte intake. Rise slowly from sitting or lying positions. If dizziness persists or worsens, contact a healthcare provider to rule out orthostatic hypotension.

Pancreatitis (acute)
RareSerious

Rare but serious adverse event reported in GLP-1 and glucagon agonists. Symptoms include severe upper abdominal pain, back pain, nausea, and vomiting. Seek immediate medical attention if these symptoms occur. Risk may be higher in individuals with personal or family history of pancreatitis. Discontinue immediately if pancreatitis is suspected.

Gallbladder issues (cholelithiasis)
UncommonModerate

Rapid weight loss increases gallstone formation risk. Symptoms include right upper quadrant pain, nausea, and vomiting. Maintain gradual weight loss (1-2 lbs per week) rather than rapid loss. Ensure adequate fat intake (20-30% of calories) to promote gallbladder emptying. Seek medical evaluation if abdominal pain occurs.

Hypoglycemia (low blood sugar)
RareModerate

Uncommon in non-diabetic individuals due to glucose-dependent insulin secretion. Risk increases significantly if combined with insulin or sulfonylureas. Diabetic users may require dose adjustment of concurrent medications. Symptoms include shakiness, sweating, rapid heartbeat, and confusion. Always carry fast-acting carbohydrates (glucose tablets, juice) if at risk.

Tachycardia (elevated heart rate)
UncommonMild

Glucagon signaling can increase heart rate. Reported in 5-10% of users. Usually mild and transient. Monitor heart rate regularly. Contact healthcare provider if heart rate remains elevated (>100 bpm at rest) or if accompanied by chest pain or shortness of breath.

Dehydration
UncommonModerate

Can result from nausea, vomiting, or diarrhea. Symptoms include dry mouth, dark urine, dizziness, and fatigue. Maintain consistent fluid intake of at least 2-3 liters of water daily. Electrolyte-containing beverages (e.g., coconut water, sports drinks) may help. Seek medical attention if dehydration symptoms persist.

Taste changes or metallic taste
RareMild

Occasionally reported with GLP-1 agonists. Usually self-resolving within 1-2 weeks. Maintain good oral hygiene and stay hydrated. Contact healthcare provider if taste changes persist beyond 2 weeks.

Hair loss (telogen effluvium)
UncommonMild

Can occur with rapid weight loss due to nutritional stress. Ensure adequate protein (1.2-1.6g per kg), iron, zinc, and B vitamins. Hair loss typically reverses 3-6 months after stabilizing weight. Consider biotin or multivitamin supplementation. Contact healthcare provider if hair loss is severe or persistent.

Muscle loss
UncommonModerate

Rapid weight loss without adequate protein intake can result in lean muscle loss. Minimize by consuming 1.2-1.6g protein per kg body weight daily and engaging in resistance training 2-3 times per week. Prioritize protein at each meal.

Dosing Reference

ParameterValue
Dose range0.5-12 mg
FrequencyOnce weekly
TimingAny time, with or without food
RouteSubcutaneous

Progressive titration: start 0.5mg, increase every 4 weeks. Max dose 12mg in trials.

Research disclaimer

Figures drawn from published research literature and community logs. Not clinical recommendations. Consult a qualified professional. Research use only.

Reconstitution Guide

Do not use saline or bacteriostatic saline — use only bacteriostatic water for reconstitution

Do not shake the vial vigorously; gentle swirling prevents peptide degradation

Discard immediately if the solution appears cloudy, discolored, or contains visible particles

Use within 30 days of reconstitution when stored at 2–8°C

Do not freeze the reconstituted solution; freezing may denature the peptide

Use the PeptideVolt reconstitution calculator for your exact concentration

Use the PeptideVolt reconstitution calculator for your exact concentration

Molecular and Pharmacological Data

Half-life5-6 days (approximate, based on Phase 2 data)

Retatrutide is a triple receptor agonist that simultaneously activates GIP (glucose-dependent insulinotropic polypeptide), GLP-1 (glucagon-like peptide-1), and glucagon receptors. This triple activation enhances insulin secretion in response to glucose, slows gastric emptying to increase satiety, and increases energy expenditure through glucagon signaling. The combined effect produces superior weight loss and metabolic improvements compared to dual GLP-1/GIP agonists like tirzepatide.

GIP Receptor Agonism

Activates GIP receptors on pancreatic beta cells to enhance glucose-dependent insulin secretion, improving glycemic control without hypoglycemia risk when glucose is normal. Also acts on adipose tissue to promote energy expenditure.

GLP-1 Receptor Agonism

Slows gastric emptying to increase satiety and reduce appetite, decreases hepatic glucose production, and enhances insulin secretion. This is the primary mechanism driving weight loss in GLP-1 agonists.

Glucagon Receptor Agonism

Increases energy expenditure and fat oxidation, particularly in brown adipose tissue. Glucagon signaling promotes lipolysis and thermogenesis, contributing to the superior weight loss profile of retatrutide versus dual agonists.

  • Retatrutide is a novel triple agonist; it activates three distinct metabolic pathways simultaneously, unlike tirzepatide (GIP/GLP-1 dual agonist)
  • Phase 2 clinical trials showed mean weight loss of 17-22% at the 12mg dose over 48 weeks, compared to 20-22% for tirzepatide at 15mg
  • The glucagon component increases energy expenditure and may reduce compensatory metabolic adaptation seen with GLP-1 monotherapy
  • Retatrutide maintains glucose-dependent insulin secretion, minimizing hypoglycemia risk in non-diabetic individuals
  • Weekly subcutaneous dosing allows for convenient self-administration and consistent pharmacokinetics

Track your Retatrutide research

Free account. No credit card required.

Start Free

Browse the Research Library

40+ peptide profiles with mechanism summaries, dosing data, and reconstitution guides.

View all peptides

Research Use Only. All content on this page is provided for informational and educational purposes related to scientific research. Retatrutide is not approved for human use by the FDA or any equivalent regulatory body. This is not medical advice. Do not use any substance discussed here for therapeutic, diagnostic, or preventative purposes. Consult a qualified healthcare professional before making any health-related decisions. The Peptide Volt does not endorse the use of any research chemicals. 18+ only.